ValiRx plc (AIM: VAL), a life science company specialising in early-stage cancer therapeutics and women's health, announced on Wednesday that its subsidiary, Inaphaea BioLabs Limited, has entered into an Evaluation and Commercial Use Agreement with Spanish contract research organisation Xenopat S.L.

This agreement allows Xenopat to utilise Inaphaea's portfolio of over 470 Patient Derived Cells (PDCs) within its in-vivo Xenograft platform.

Under the terms of the contract, Inaphaea will receive an upfront fee and a share of service royalties from the commercialisation of these models. Both companies have committed to co-marketing their services and pursuing non-dilutive funding through European grant schemes to further enhance their collaboration. The initial term of the agreement is set for 12 months, with the possibility of extension by mutual consent.

ValiRx aims to accelerate the development of innovative medicines by providing the scientific, financial and commercial support necessary for translating novel drug candidates from pre-clinical studies to clinical development. The company connects various disciplines to streamline the drug development process and partners with investors for further clinical advancement and commercialisation of lead candidates from its portfolio.